What happened when BIEL Studied data on reducing c
Post# of 7790
(Total Views: 291)
Posted On: 07/04/2024 9:26:51 PM
What happened when BIEL Studied data on reducing chronic pain drug use with PEMF therapy
A Prospective Six-Month Study of Chronic Pain Sufferers: A NovelOTC Neuromodulation Therapy
(published 9/30/2019)
Conclusion
"Electroceuticals offer immense potential as a non-pharmacological intervention for chronic pain management. Current over-the-counter electroceuticals, such as TENS devices, rely on skin contact to achieve neuromodulation. However, continuous/recurring use of TENS is limited due to the potential for skin damage, need for short use duration (typically, less than 30 mins, twice a day), and unpleasant sensations (shocks, tingling). PSWT electroceuticals, on the other hand, use electromagnetic fields (EMF), which easily pass through skin/bandaging, can be incorporated into wraps/braces and are well tolerated by patients owing to a lack of any sensation during use. This prospective study involved a 6-month assessment of 240 chronic pain subjects, who at the time of enrollment had obtained pain relief after 7days of treatment with a commercially available PSWT electroceutical device. The results indicate that pain relief was sustained for 6 months in over 85% of subjects. In addition, subjects reported a substantial improvement in functionality through measures such as physical activity, sleep quality, and overall quality of life. They also decreased consumption of pain medication, including prescription and opioid-based pain medications."
"A major objective of any electroceutical is to serve as an effective adjunct for multimodal pain management. PSWT was found to be consistently effective in providing pain relief for varying pain etiologies and in multiple anatomical lo-cations. Given the lack of adverse effects and ability of patients to tolerate long-term PSWT use, it is the authors’ conclusion that PSWT is an effective, over-the-counter electroceutical therapy for a substantial portion of the chronic pain population"
Table 3: Analgesic medications used by the study sample. Analgesics Fraction of users (%)
NSAIDS (e.g., ibuprofen) 43
Paracetamol 61
Weak opioids (e.g., codeine) 25
Strong opioids (e.g., hydrocodone) 11
Tramadol or equivalent 8
Pregabalin (e.g., Lyrica) 8
Amitriptyline 17
Topical opioid (e.g., morphine) 8
Topical NSAIDS (e.g., Voltarol) 21
Gabapentin 2
Other 4
No analgesics 5
Note: medication use data were available for only 172 out of the 240subjects.
https://onlinelibrary.wiley.com/doi/epdf/10.1...19/3154194
A Prospective Six-Month Study of Chronic Pain Sufferers: A NovelOTC Neuromodulation Therapy
(published 9/30/2019)
Conclusion
"Electroceuticals offer immense potential as a non-pharmacological intervention for chronic pain management. Current over-the-counter electroceuticals, such as TENS devices, rely on skin contact to achieve neuromodulation. However, continuous/recurring use of TENS is limited due to the potential for skin damage, need for short use duration (typically, less than 30 mins, twice a day), and unpleasant sensations (shocks, tingling). PSWT electroceuticals, on the other hand, use electromagnetic fields (EMF), which easily pass through skin/bandaging, can be incorporated into wraps/braces and are well tolerated by patients owing to a lack of any sensation during use. This prospective study involved a 6-month assessment of 240 chronic pain subjects, who at the time of enrollment had obtained pain relief after 7days of treatment with a commercially available PSWT electroceutical device. The results indicate that pain relief was sustained for 6 months in over 85% of subjects. In addition, subjects reported a substantial improvement in functionality through measures such as physical activity, sleep quality, and overall quality of life. They also decreased consumption of pain medication, including prescription and opioid-based pain medications."
"A major objective of any electroceutical is to serve as an effective adjunct for multimodal pain management. PSWT was found to be consistently effective in providing pain relief for varying pain etiologies and in multiple anatomical lo-cations. Given the lack of adverse effects and ability of patients to tolerate long-term PSWT use, it is the authors’ conclusion that PSWT is an effective, over-the-counter electroceutical therapy for a substantial portion of the chronic pain population"
Table 3: Analgesic medications used by the study sample. Analgesics Fraction of users (%)
NSAIDS (e.g., ibuprofen) 43
Paracetamol 61
Weak opioids (e.g., codeine) 25
Strong opioids (e.g., hydrocodone) 11
Tramadol or equivalent 8
Pregabalin (e.g., Lyrica) 8
Amitriptyline 17
Topical opioid (e.g., morphine) 8
Topical NSAIDS (e.g., Voltarol) 21
Gabapentin 2
Other 4
No analgesics 5
Note: medication use data were available for only 172 out of the 240subjects.
https://onlinelibrary.wiley.com/doi/epdf/10.1...19/3154194
(2)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼